Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ELAB
ELAB logo

ELAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.000
Open
7.000
VWAP
11.52
Vol
43.61M
Mkt Cap
16.23M
Low
6.558
Amount
502.37M
EV/EBITDA(TTM)
--
Total Shares
1.16M
EV
2.39M
EV/OCF(TTM)
--
P/S(TTM)
0.04
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company manages and operates a diverse portfolio of five wholly owned subsidiaries: NorthStrive BioSciences Inc., PMGC Research Inc., PMGC Capital LLC, Pacific Sun Packaging Inc., and AGA Precision Systems LLC. NorthStrive BioSciences Inc. is a biopharmaceutical company focusing on the development and acquisition of aesthetic medicines and therapeutic products. PMGC Research Inc. is engaged in medical scientific research and development efforts. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging Inc. is a custom information technology packaging company. AGA Precision Systems LLC is a precision engineering and CNC machining company.
Show More

Events Timeline

(ET)
2026-04-01
10:10:00
PMGC Holdings Inc Trading Halted Due to Volatility
select
2026-03-27 (ET)
2026-03-27
16:10:00
PMGC Holdings' Subsidiary Amends Agreement with MOA Life Plus
select
2026-03-24 (ET)
2026-03-24
07:20:00
PMGC Holdings Completes ITAR Registration, Enhances SVM's Supplier Qualification
select
2026-03-10 (ET)
2026-03-10
07:40:00
PMGC Holdings Initiates Preclinical Study for EL-32
select
2026-03-09 (ET)
2026-03-09
19:50:00
PMGC Holdings Inc Trading Halted, News Pending
select
2026-02-19 (ET)
2026-02-19
07:40:00
PMGC Holdings Subsidiary Files Ten New Patents
select
2026-02-11 (ET)
2026-02-11
07:40:00
PMGC Subsidiary NorthStrive Signs Exclusive License Agreement with Modulant
select
2026-02-03 (ET)
2026-02-03
07:40:00
PMGC Holdings Completes Acquisition of SVM Machining
select

News

Newsfilter
9.5
03-30Newsfilter
PinnedPMGC Holdings Releases Annual Report for Fiscal Year 2025
  • Capital Allocation Growth: PMGC Holdings achieved a 43% increase in total assets for fiscal year 2025, rising from approximately $8.99 million to $12.87 million, while shareholders' equity grew from about $6.66 million to $7.84 million, reflecting successful capital deployment and balance sheet expansion that enhances financial stability.
  • Acquisition Strategy Implementation: During fiscal year 2025, PMGC completed three acquisitions in precision manufacturing and industrial packaging, with these businesses characterized by high technical barriers and mission-critical applications, which are expected to enhance the company's market competitiveness and customer retention.
  • Industry Demand Drivers: The acquisitions position PMGC favorably within precision manufacturing and specialty IT hardware packaging sectors, with ongoing U.S. defense spending and data center infrastructure development expected to sustain demand for its products, ensuring long-term growth potential.
  • Biopharmaceutical Advancements: PMGC's biopharmaceutical subsidiary, Northstrive Biosciences, advanced multiple clinical and preclinical initiatives in fiscal year 2025, focusing on muscle preservation, which is anticipated to open new market opportunities through potential combinations with GLP-1 therapies.
stocktwits
7.5
03-31stocktwits
ELAB Partners with Turbo-Jet for Long-Term Supply Agreement
  • Long-Term Agreement: ELAB's AGA Precision Systems has signed a five-year long-term agreement with Turbo-Jet Products Co. to supply mission-critical components for commercial and defense programs, further solidifying AGA's role in the aerospace and defense supply chain.
  • Significant Asset Growth: PMGC recently reported a 43% increase in total assets to $12.9 million in 2025, up from $9 million in 2024, indicating successful acquisition strategies in sectors with steady demand, enhancing its market competitiveness.
  • Stock Price Surge: Following the partnership with Turbo-Jet, ELAB's stock rose by 7% on Tuesday, reflecting market optimism regarding the company's future growth potential, particularly in supporting defense projects.
  • Successful ITAR Registration: PMGC's subsidiary SVM Machining has secured ITAR registration from the U.S. Department of State, allowing it to engage in controlled defense projects, thereby enhancing its capability to enter U.S. military supply chains and signaling future business expansion potential.
Newsfilter
7.5
03-31Newsfilter
AGA Precision Systems Signs Long-Term Agreement with Turbo-Jet Products
  • Long-Term Agreement: AGA Precision Systems has executed a five-year Long-Term Agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components, thereby ensuring a strategic partnership for future purchase orders.
  • Compliance Enhancement: This agreement supports the execution of U.S. government and defense-related contracts, as AGA strengthens its position in the aerospace supply chain through AS9100 certification and ITAR compliance, ensuring high-quality and compliant component delivery.
  • Market Positioning Improvement: By collaborating with Turbo-Jet, AGA not only solidifies its market position in the aerospace and defense sectors but also lays the groundwork for future business growth, particularly in meeting stringent Federal Acquisition Regulations.
  • Technical Capability Showcase: AGA's precision CNC machining capabilities enable it to meet demanding technical specifications for complex metal processing, further enhancing its competitiveness in the aerospace, defense, and industrial sectors.
stocktwits
8.5
03-30stocktwits
PMGC Holdings Unit Amends Clinical Trial Agreement
  • Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
  • Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
  • Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
  • FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
stocktwits
4.5
03-30stocktwits
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
  • PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.

  • Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.

  • Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.

  • Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."

Newsfilter
7.5
03-27Newsfilter
PMGC Subsidiary Amends License Agreement with MOA
  • License Agreement Amendment: PMGC Holdings Inc.'s wholly owned subsidiary, NorthStrive Biosciences, has amended its existing License Agreement with South Korea's MOA Life Plus Co., Ltd., updating the timelines and key development milestones for the EL-32 and EL-22 human clinical development programs, thereby enhancing the company's competitive position in the biopharmaceutical sector.
  • Commitment to Development: This amendment not only reflects NorthStrive Biosciences' commitment to disciplined development planning but also indicates the company's ongoing efforts to advance its human health portfolio, which is expected to accelerate product launch timelines and improve market acceptance.
  • Strategic Partnership Enhancement: By collaborating with MOA Life Plus, NorthStrive Biosciences can leverage MOA's expertise in biotechnology to further drive the development of innovative therapies, thereby increasing the company's influence in the global market.
  • Market Outlook: As clinical development progresses for products like EL-22, NorthStrive Biosciences is poised to achieve breakthroughs in obesity treatment, particularly in preserving muscle mass, which will create new growth opportunities and enhance its standing in the biopharmaceutical industry.

Valuation Metrics

The current forward P/E ratio for PMGC Holdings Inc (ELAB.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess PMGC Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

I need all stocks that about to halt?
Intellectia · 22 candidates
Price Change Pct: $-100.00 - $-8.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASENews Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
ITRM logo
ITRM
Iterum Therapeutics PLC
1.90M
BUR logo
BUR
Burford Capital Ltd
906.24M
LTRN logo
LTRN
Lantern Pharma Inc
12.53M
ONCO logo
ONCO
Onconetix Inc
1.35M
AMPG logo
AMPG
Amplitech Group Inc
45.60M
SLND logo
SLND
Southland Holdings Inc
66.02M
stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M

Whales Holding ELAB

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is PMGC Holdings Inc (ELAB) stock price today?

The current price of ELAB is 14 USD — it has increased 133.72

What is PMGC Holdings Inc (ELAB)'s business?

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company manages and operates a diverse portfolio of five wholly owned subsidiaries: NorthStrive BioSciences Inc., PMGC Research Inc., PMGC Capital LLC, Pacific Sun Packaging Inc., and AGA Precision Systems LLC. NorthStrive BioSciences Inc. is a biopharmaceutical company focusing on the development and acquisition of aesthetic medicines and therapeutic products. PMGC Research Inc. is engaged in medical scientific research and development efforts. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging Inc. is a custom information technology packaging company. AGA Precision Systems LLC is a precision engineering and CNC machining company.

What is the price predicton of ELAB Stock?

Wall Street analysts forecast ELAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is PMGC Holdings Inc (ELAB)'s revenue for the last quarter?

PMGC Holdings Inc revenue for the last quarter amounts to 285.95K USD, decreased

What is PMGC Holdings Inc (ELAB)'s earnings per share (EPS) for the last quarter?

PMGC Holdings Inc. EPS for the last quarter amounts to -117.82 USD, decreased -98.52

How many employees does PMGC Holdings Inc (ELAB). have?

PMGC Holdings Inc (ELAB) has 2 emplpoyees as of April 02 2026.

What is PMGC Holdings Inc (ELAB) market cap?

Today ELAB has the market capitalization of 16.23M USD.